Handelsbanken Fonder AB acquired a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 178,700 shares of the company's stock, valued at approximately $3,937,000. Handelsbanken Fonder AB owned 0.09% of Cellebrite DI at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. FMR LLC lifted its position in Cellebrite DI by 136.3% in the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company's stock valued at $94,586,000 after acquiring an additional 3,239,307 shares in the last quarter. Meitav Investment House Ltd. boosted its position in shares of Cellebrite DI by 29.7% during the third quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company's stock worth $34,797,000 after buying an additional 473,293 shares during the period. Pembroke Management LTD grew its holdings in shares of Cellebrite DI by 4.4% during the fourth quarter. Pembroke Management LTD now owns 1,992,432 shares of the company's stock worth $43,893,000 after buying an additional 84,087 shares in the last quarter. Principal Financial Group Inc. bought a new position in shares of Cellebrite DI during the third quarter worth about $23,402,000. Finally, Two Sigma Advisers LP raised its position in Cellebrite DI by 9.8% in the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company's stock valued at $22,584,000 after buying an additional 120,000 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
CLBT has been the subject of several research reports. Craig Hallum raised their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Lake Street Capital raised their price objective on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of Cellebrite DI in a research report on Friday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $23.43.
Check Out Our Latest Stock Report on Cellebrite DI
Cellebrite DI Price Performance
NASDAQ CLBT traded down $0.54 during trading on Thursday, reaching $18.50. 2,513,319 shares of the company's stock were exchanged, compared to its average volume of 2,151,755. The business has a 50 day moving average price of $22.44 and a 200-day moving average price of $19.54. The stock has a market capitalization of $3.81 billion, a P/E ratio of -13.31, a PEG ratio of 4.27 and a beta of 1.47. Cellebrite DI Ltd. has a fifty-two week low of $10.24 and a fifty-two week high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
